Literature DB >> 33118247

Mucosal pathogenesis in gastro-esophageal reflux disease.

Ahsen Ustaoglu1, Anh Nguyen2, Stuart Spechler2, Daniel Sifrim1, Rhonda Souza2, Philip Woodland1.   

Abstract

BACKGROUND: Despite gastro-esophageal reflux disease affecting up to 20% of Western populations, relatively little is known about the molecular mechanisms underlying its most troublesome symptom: heartburn. Recent findings have unveiled the role of components of the esophageal mucosa in the pathogenesis of GERD including sensory nociceptive nerves and inflammatory mediators. Erosive esophagitis was long believed to develop as a result of acid injury at the esophageal lumen, but novel concepts suggest the generation of reflux-induced esophageal injury as a result of cytokine-mediated inflammation. Moreover, the localization and characterization of mucosal afferent nerves vary between GERD phenotypes and could explain the heterogeneity of symptom perception between patients who experience similar levels of acid reflux.
PURPOSE: The purpose of this review is to consider the crosstalk of different factors of the esophageal mucosa in the pathogenesis of GERD, with a particular focus on mucosal innervation and molecular basis of acid-induced cytokine response. We discuss the current understanding of the mucosal response to acid injury, the nociceptive role of acid-sensitive receptors expressed in the esophageal mucosa, and the role of esophageal epithelial cells in initiating the onset of erosive esophagitis.
© 2020 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CGRP (calcitonin gene-related peptide); GERD (gastro-esophageal reflux disease); ROS (reactive oxygen species); inflammation; nociceptors

Year:  2020        PMID: 33118247     DOI: 10.1111/nmo.14022

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  7 in total

1.  Proanthocyanidins mitigate bile acid-induced changes in GSTT2 levels in a panel of racially diverse patient-derived primary esophageal cell cultures.

Authors:  Katherine M Weh; Danielle K Turgeon; Joel H Rubenstein; Jennifer L Clarke; Amy B Howell; Andrew C Chang; Laura A Kresty
Journal:  Mol Carcinog       Date:  2021-11-10       Impact factor: 4.784

2.  Network Pharmacology Analysis of Hewei Jiangni Granule for Gastroesophageal Reflux Disease and Experimental Verification of Its Anti-Neurogenic Inflammation Mechanism.

Authors:  Yuan Cheng; Fushun Kou; Xiaosi Zhang; Yi Dai; Lei Shi; Chune Xie; Xiaohong Li; Junxiang Li
Journal:  Drug Des Devel Ther       Date:  2022-05-05       Impact factor: 4.319

3.  Identification of Unique Transcriptomic Signatures and Hub Genes Through RNA Sequencing and Integrated WGCNA and PPI Network Analysis in Nonerosive Reflux Disease.

Authors:  Ye Zhao; Teng Ma; Duowu Zou
Journal:  J Inflamm Res       Date:  2021-11-23

4.  Cranberry Polyphenols in Esophageal Cancer Inhibition: New Insights.

Authors:  Katherine M Weh; Yun Zhang; Connor L Howard; Amy B Howell; Jennifer L Clarke; Laura A Kresty
Journal:  Nutrients       Date:  2022-02-24       Impact factor: 5.717

5.  Higher Dementia Risk in People With Gastroesophageal Reflux Disease: A Real-World Evidence.

Authors:  Shuo-Yan Gau; Jung-Nien Lai; Hei-Tung Yip; Meng-Che Wu; James Cheng-Chung Wei
Journal:  Front Aging Neurosci       Date:  2022-04-04       Impact factor: 5.750

6.  Atrophic gastritis is inversely associated with gastroesophageal reflux disease in a twin register based study.

Authors:  Ji Zhang; Rino Bellocco; Joar Franzén; Ulrika Zagai; Patrik K E Magnusson; Weimin Ye
Journal:  United European Gastroenterol J       Date:  2022-06-22       Impact factor: 6.866

7.  Herbal Medicine Hewei Jiangni Decoction Is Noninferior to Oral Omeprazole for the Treatment of Nonerosive Gastroesophageal Reflux Disease: A Randomized, Double-Blind, and Double-Dummy Controlled Trail.

Authors:  Feng Li; Yali Yuan; Di Wu; Junxiang Li; Haixiao Han; Xiaohong Li; Liming Hu; Runhua Chen; Yupu Yao; Yao Jiao; Huihui Chen; Tangyou Mao; Chune Xie
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-22       Impact factor: 2.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.